Biological and Environmental Research Ontology

Last uploaded: December 23, 2022

Id	http://purl.obolibrary.org/obo/NCIT_C116628 http://purl.obolibrary.org/obo/NCIT_C116628
Preferred Name	Duligotuzumab
Definitions	An immunoglobulin (Ig) G1 monoclonal antibody directed against both human epidermal growth factor receptor 3 (HER3 or ERBB3) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Duligotuzumab binds to both EGFR and HER3 and inhibits their activation. This may prevent EGFR/HER3-mediated signaling and inhibit EGFR/HER3-dependent tumor cell proliferation. In addition, MEHD7945A induces antibody-dependent cell-mediated cytotoxicity (ADCC) against EGR/HER3-expressing tumor cells. EGFR and HER3, members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in tumors; their expression is associated with both poor prognosis and drug resistance.
Type	http://www.w3.org/2002/07/owl#Class

definition	An immunoglobulin (Ig) G1 monoclonal antibody directed against both human epidermal growth factor receptor 3 (HER3 or ERBB3) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Duligotuzumab binds to both EGFR and HER3 and inhibits their activation. This may prevent EGFR/HER3-mediated signaling and inhibit EGFR/HER3-dependent tumor cell proliferation. In addition, MEHD7945A induces antibody-dependent cell-mediated cytotoxicity (ADCC) against EGR/HER3-expressing tumor cells. EGFR and HER3, members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in tumors; their expression is associated with both poor prognosis and drug resistance.
prefLabel	Duligotuzumab
label	Duligotuzumab
PDQ_Closed_Trial_Search_ID	686389
code	C116628
Has_Target	http://purl.obolibrary.org/obo/NCIT_C18490 http://purl.obolibrary.org/obo/NCIT_C17068
prefixIRI	NCIT:C116628
in_subset	http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 http://purl.obolibrary.org/obo/NCIT_C157711 http://purl.obolibrary.org/obo/NCIT_C157712 See more See less
Display_Name	Duligotuzumab
Preferred_Name	Duligotuzumab
FDA_UNII_Code	8PMF8YQX2T
Contributing_Source	CTRP FDA
Maps_To	Duligotuzumab
CAS_Registry	1312797-14-0
NCI_Drug_Dictionary_ID	686389
type	http://www.w3.org/2002/07/owl#Class
Is_Value_For_GDC_Property	http://purl.obolibrary.org/obo/NCIT_C1909
subClassOf	http://purl.obolibrary.org/obo/NCIT_C20401
PDQ_Open_Trial_Search_ID	686389
Semantic_Type	Pharmacologic Substance
UMLS_CUI	C3490133

Add comment

Add proposal

Subscribe to notes emails

Delete	Subject	Author	Type	Created
No notes to display